J Pathol Transl Med.  2021 May;55(3):235-235. 10.4132/jptm.2021.04.28.

Histologic subtyping of ampullary carcinoma for targeted therapy

• Hong SM

• KMID: 2515929
• DOI: http://doi.org/10.4132/jptm.2021.04.28

Reference

References

1. Regalla DK, Jacob R, Manne A, Paluri RK. Therapeutic options for ampullary carcinomas: a review. Oncol Rev. 2019; 13:440.

2. Kumari N, Singh RK, Mishra SK, Krishnani N, Mohindra S, L R. Identification of PI3K-AKT signaling as the dominant altered pathway in intestinal type ampullary cancers through whole-exome sequencing. J Pathol Tansl Med. 2021; 55:192–201.

3. Hechtman JF, Liu W, Sadowska J, et al. Sequencing of 279 cancer genes in ampullary carcinoma reveals trends relating to histologic subtypes and frequent amplification and overexpression of ERBB2 (HER2). Mod Pathol. 2015; 28:1123–9.

4. Gingras MC, Covington KR, Chang DK, et al. Ampullary cancers harbor ELF3 tumor suppressor gene mutations and exhibit frequent WNT dysregulation. Cell Rep. 2016; 14:907–19.

5. Yachida S, Wood LD, Suzuki M, et al. Genomic sequencing identifies ELF3 as a driver of ampullary carcinoma. Cancer Cell. 2016; 29:229–40.

6. Kwon MJ, Kim JW, Jung JP, et al. Low incidence of KRAS, BRAF, and PIK3CA mutations in adenocarcinomas of the ampulla of Vater and their prognostic value. Hum Pathol. 2016; 50:90–100.